<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Daniel Benjamin Jr | PKMS Lab | UBC</title>
    <link>https://a2mahara.github.io/author/daniel-benjamin-jr/</link>
      <atom:link href="https://a2mahara.github.io/author/daniel-benjamin-jr/index.xml" rel="self" type="application/rss+xml" />
    <description>Daniel Benjamin Jr</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Thu, 04 Jun 2020 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://a2mahara.github.io/images/icon_hu254a632e13bbcb0db1c9ac000befa917_11344_512x512_fill_lanczos_center_2.png</url>
      <title>Daniel Benjamin Jr</title>
      <link>https://a2mahara.github.io/author/daniel-benjamin-jr/</link>
    </image>
    
    <item>
      <title>Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019</title>
      <link>https://a2mahara.github.io/publication/hcq_jama/</link>
      <pubDate>Thu, 04 Jun 2020 00:00:00 +0000</pubDate>
      <guid>https://a2mahara.github.io/publication/hcq_jama/</guid>
      <description>&lt;p&gt;Our model-based analysis, published in &lt;em&gt;JAMA Pediatrics&lt;/em&gt;, sought to identify pediatric dosages for two expirimental COVID-19 therapies (hydroxychloroquine and remdesivir). A combination of PBPK modeling and allometry was used to define pediatric dosages for different development stages. Interestingly, our PBPK model analysis indicated that hydroxychloroquine lung concentrations would fall well below those needed to illicit an antiviral effect, raising concerns of its effectiveness for COVID-19 treatment.&lt;/p&gt;
&lt;br/&gt;
&lt;div class=&#34;alert alert-note&#34;&gt;
  &lt;div&gt;
    Maharaj, A. R., Wu, H., Hornik, C. P., Balevic, S. J., Hornik, C. D., Smith, P. B., Gonzalez, D., Zimmerman, K. O., Benjamin, D. K., Jr, &amp;amp; Cohen-Wolkowiez, M. (2020). Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. &lt;em&gt;JAMA Pediatrics&lt;/em&gt;, 174(10), e202422. &lt;a href=&#34;https://doi.org/10.1001/jamapediatrics.2020.2422&#34;&gt;https://doi.org/10.1001/jamapediatrics.2020.2422&lt;/a&gt;
  &lt;/div&gt;
&lt;/div&gt;
</description>
    </item>
    
  </channel>
</rss>
